Chairman of the Board; Partner, Red Sky Partners
Gregory D. Phelps has been a member of our board of directors since 2008 and has served as Chairman of the Board since 2009. Mr. Phelps is an independent advisor to biotechnology and pharmaceutical companies. He was a founder and Partner of Red Sky Partners LLC, an advisory firm providing corporate development, product strategy and leadership support to life sciences companies, from 2009 to 2014. Prior to that, Mr. Phelps served as Chairman and Chief Executive Officer of RenaMed Biologics, Inc., a private biotechnology company developing a therapeutic treatment for Acute Kidney Injury, from 2004 to 2007. His previous executive management roles include Chief Executive Officer of Ardais Corporation (2002-2003), Vice Chairman and member of the executive committee of Dyax Corporation (1998-2002), Executive Vice President and Senior Vice President of Genzyme Corporation (1991-1997), Chief Executive Officer of Viagene, Inc. (1988-1990), Chief Executive Officer of ZymoGenetics, Inc. (1986-1988) and various management positions with Baxter Travenol Laboratories, Inc., now Baxter International, Inc. (1975-1986), most recently as Vice President. Mr. Phelps’ previous board directorships include Charles River School (2004-2011, board chairman 2008-2011), EPIX Pharmaceuticals Inc. (2004-2009), Ostex International Inc. (1995-2001), Atlantic Biopharmaceuticals, now Merrimack Pharmaceuticals Inc. (1998-2000), Neozyme II Corporation (1992-1996), Genzyme Transgenics Corporation, now rEVO Biologics (1993-1995) and the Hemophilia Foundation of California (1982-1984). Mr. Phelps received a B.S. in electrical engineering from Bradley University and an M.B.A. from Harvard Business School.